| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
METTL3/METTL14 complex and viral proteases. Antiviral agent 24 inhibits METTL3/METTL14 activity, which is involved in RNA methylation, and also inhibits viral proteases. Resistance arises through structural mutations in catalytic residues such as E166A and L50F.
|
|---|---|
| ln Vitro |
Antiviral agent 24 (compound 25) has an EC50 value of 129 µM and inhibits the activity of the METTL3/METTL14 complex, with a range of 0-1000 µM[1].
Antiviral agent 24 is an effective antiviral agent with EC₅0 values of 0.101, 19.9, and 91.2 uM against EV71, CVA21, and EV68, respectively. It inhibits METTL3/METTL14 complex activity with an EC₅0 of 129 uM in a dose-dependent manner at concentrations ranging from 0 to 1000 uM. |
| ln Vivo |
No detailed in vivo activity data has been reported for Antiviral agent 24. As a research compound with antiviral activity, it could potentially be evaluated in animal models of enterovirus infection, but specific in vivo data are not available in the literature.
|
| Enzyme Assay |
METTL3/METTL14 enzymatic assays: The compound is incubated with purified METTL3/METTL14 complex and its substrate (RNA) in the presence of S-adenosylmethionine (SAM). Methyltransferase activity is measured by detecting methylated RNA products. IC₅0 or EC₅0 values are calculated from dose-response curves. Antiviral activity can be assessed using viral protease inhibition assays.
|
| Cell Assay |
Antiviral activity is assessed in cell culture using enterovirus-infected cells (e.g., EV71, CVA21, EV68). Cells are treated with serial dilutions of Antiviral agent 24, and viral replication is measured by plaque reduction assays, qPCR, or cytopathic effect (CPE) inhibition. EC₅0 values are calculated from dose-response curves. METTL3/METTL14 inhibition is confirmed in cell-based assays by measuring m6A methylation levels.
|
| Animal Protocol |
No in vivo animal model data has been reported for Antiviral agent 24. As an antiviral compound, it could potentially be evaluated in mouse models of enterovirus infection, with efficacy assessed by viral load reduction, symptom improvement, and survival.
|
| ADME/Pharmacokinetics |
Antiviral agent 24 has a molecular weight of 425.36 and a molecular formula of C1₈H1₈F3N₅O4. It is soluble in DMSO at 250 mg/mL. Storage conditions: -20degC. Detailed pharmacokinetic parameters have not been reported.
|
| Toxicity/Toxicokinetics |
No toxicity data has been published for Antiviral agent 24. As a research compound, it is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
Antiviral agent 24 is a potent antiviral compound against enteroviruses including EV71, CVA21, and EV68. It also inhibits METTL3/METTL14 complex activity. The compound is for research use only and has not entered clinical trials.
|
| Molecular Formula |
C18H18N5O4F3
|
|---|---|
| Molecular Weight |
425.362
|
| Exact Mass |
425.131
|
| CAS # |
23661-03-2
|
| PubChem CID |
44423866
|
| Appearance |
White to off-white solid powder
|
| LogP |
2
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
30
|
| Complexity |
589
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
FC(F)(F)C1=CC=CC(CNC2=NC=NC3=C2N=CN3[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)=C1
|
| InChi Key |
SDQKDCSBWUSBDO-LSCFUAHRSA-N
|
| InChi Code |
InChI=1S/C18H18F3N5O4/c19-18(20,21)10-3-1-2-9(4-10)5-22-15-12-16(24-7-23-15)26(8-25-12)17-14(29)13(28)11(6-27)30-17/h1-4,7-8,11,13-14,17,27-29H,5-6H2,(H,22,23,24)/t11-,13-,14-,17-/m1/s1
|
| Chemical Name |
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[3-(trifluoromethyl)phenyl]methylamino]purin-9-yl]oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 250 mg/mL (587.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.89 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3509 mL | 11.7547 mL | 23.5095 mL | |
| 5 mM | 0.4702 mL | 2.3509 mL | 4.7019 mL | |
| 10 mM | 0.2351 mL | 1.1755 mL | 2.3509 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
